Jul 22, 2026 04:30PM
Jul 22, 2026 04:30PM
Jul 10, 2026 11:23AM
Jul 10, 2026 11:23AM
May 30, 2026 08:00AM
May 18, 2026 08:00AM
May 14, 2026 10:55AM "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
May 12, 2026 09:04AM
May 12, 2026 09:00AM
Apr 30, 2026 09:00AM
Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM
Mar 19, 2026 06:45AM
Feb 27, 2026 10:04AM PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
Feb 27, 2026 10:00AM
Jan 8, 2026 10:30AM
Dec 17, 2025 06:45AM
Dec 10, 2025 06:30PM
Dec 5, 2025 08:00AM
Nov 21, 2025 01:24PM
Nov 21, 2025 01:24PM U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
Oct 23, 2025 08:00AM
Oct 22, 2025 08:00AM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
Oct 19, 2025 07:30PM
Oct 14, 2025 08:00PM
Oct 8, 2025 07:30PM Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
May 1, 2025 09:00AM
Feb 13, 2025 10:00AM
Feb 12, 2025 06:32PM
Jan 8, 2025 06:30PM
Dec 5, 2024 08:49AM
Nov 20, 2024 01:00PM
Oct 18, 2024 02:13PM Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
Oct 10, 2024 01:00PM
Oct 10, 2024 06:51AM
Sep 24, 2024 02:05AM
Sep 18, 2024 07:30PM
Sep 4, 2024 08:00AM
Aug 27, 2024 07:30PM
Jul 26, 2024 11:39AM Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
May 30, 2024 10:30PM
Apr 23, 2024 07:30PM
Mar 28, 2024 11:00AM
Mar 26, 2024 08:30AM
Mar 22, 2024 08:00AM
Mar 11, 2024 09:00AM
Feb 15, 2024 06:30PM PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-L
Feb 1, 2024 07:00AM

327,201 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All